| This week's sponsor is FierceBiotech Executive Breakfast at BIO 2018. | | | |
| Welcome to FierceLifeSci Weekly Digest, your roundup of the biggest and most popular stories from each of our publications. | |
|
Featured Story | | | Wednesday, May 30, 2018 The head of North American communications for Sanofi woke up Wednesday to the news that actress Roseanne Barr had blamed her recent racist tweet on the use of the company's insomnia drug, Ambien. But Sanofi wasn’t having it. |
|
|
Top Stories Of The Week Thursday, May 31, 2018 Novartis continues its hemorrhaging of executives seeking new careers at smaller, younger biotechs as its EVP and head of U.S. oncology Bill Hinshaw takes the reins at Axcella Health. Thursday, May 31, 2018 Want to get serious about business development? Take a page from Pfizer’s playbook—and that’s exactly what Biogen is doing. On Thursday, the big biotech said it recruited veteran Dan Karp in a revamp of its BD and corporate strategy team. Wednesday, May 30, 2018 Craig Venter, Ph.D., is leaving Human Longevity Inc. Venter’s decision to step down as CEO and return to research at the J. Craig Venter Institute continues the turnover at the top of HLI, which has now lost two CEOs and a CMO in the past six months. Tuesday, May 29, 2018 Looks like Merck’s Keytruda could get some company in the lung cancer chemo-combo department. On Monday, nemesis Roche said its Tecentriq, in combination with carboplatin and Celgene’s Abraxane, had topped solo chemo at helping previously untreated patients live longer and at keeping disease at bay. Friday, May 25, 2018 Novartis has been looking to jettison some assets in its North American generics business, but as it turns out, a manufacturing facility in Canada will be sold off first. Its buyer, Avara, will add the Sandoz plant to a series of Big Pharma pickups over the past year. Tuesday, May 29, 2018 WuXi AppTec reminded traders to consider the risks of investing in CROs after its stock price increased by the daily maximum of 10% for 15 straight trading sessions following its Shanghai IPO earlier this month. That vaulted its market cap to over $21 billion. Friday, May 25, 2018 A team at the National Cancer Institute has discovered how bacteria in the gut affect antitumor immune responses in the liver, a connection that could be exploited to find new therapies for liver cancer. Wednesday, May 30, 2018 Titan Pharmaceuticals and Braeburn are parting ways over an opioid treatment licensing deal inked in 2012. Wednesday, May 30, 2018 A new study shows that when doctors were persistent in encouraging HPV vaccination, 94% of children were vaccinated. Enrollment Showcase | | | Sponsored by: Bioinformatics at UTHealth SBMI UTHealth SBMI now offers a M.S. track in clinical and translational bioinformatics. |
|
|
Resources Sponsored by: Blue Latitude Health Blue Latitude Health explores the commercial barriers and new stakeholder connections for pharma companies developing precision medicines, and reveals how to grasp novel opportunities in the new era of healthcare. Presented by: Patheon, part of Thermo Fisher Scientific “Faster and better” has become the mantra for biopharmaceutical companies as they face intense pressure to get therapies to market faster. Quickly proving efficacy in first-in-human (FIH) trials is a make-or-break milestone for these cash-strapped companies whose hopes hinge upon one or two molecules. Read how CDMOs are responding to this pressure. Sponsored by: Veeva Systems Learn how cloud-enabled solutions provide real-time insights and actionable analytics to improve clinical trial safety and performance in this short presentation. Sponsored by: Veeva Systems Find out how to eliminate regulatory’s tracking spreadsheets for good. Sponsored by: Veeva Systems UCB took a more holistic approach to managing regulatory processes. Read how their efforts are paying off. Sponsored by: Veeva Systems Learn how to reduce change management burden, keep systems current, and maintain compliance by applying a risk-based approach to change management of GxP systems. Sponsored by: DocuSign Life science companies are experiencing a significant transformation in how they bring new products to market. |
